MASTER THESIS STUDENT CANCER IMMUNOTHERAPY / BISPECIFIC ANTIBODIES (BIOLOGY GROUP)

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, dedicated to developing innovative biopharmaceuticals for cancer therapy. Philochem AG is the discovery R&D center of the Philogen Group located in Otelfingen (Zurich, Switzerland). Promising preclinical candidates developed at Philochem are subsequently produced at Philogen’s authorized Good Manufacturing Practice (GMP) facilities in Siena (Italy). The Company currently sponsors and coordinates Phase I, II and III prospective clinical trials in Europe and in the United States. Despite the focus on cancer research, the company is also active in discovering innovative therapies for inflammatory conditions

Philochem operates with four key departments:

• Discovery of innovative therapeutic proteins
• Development of GMP-ready mammalian cell lines expressing therapeutic proteins
• Creating diagnostic and therapeutic targeted small organic molecules
• Bridging Biology and...